Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-28
2010-10-12
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S327000, C530S328000, C435S007230, C435S007100, C514S015800
Reexamination Certificate
active
07811993
ABSTRACT:
Novel BRAFV600Emutant peptides or a pharmaceutically acceptable salt thereof, that induce MHC Class I-dependent cytotoxic T cell responses in mammals are useful in prophylactic, diagnostic and therapeutic treatments for melanoma. Such compounds are also useful in drug development for non-peptide mimics of the compounds described herein and in the development of therapeutic or diagnostic antibodies.
REFERENCES:
Purev E, et al., “Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, ΔEGF-R, and de2-7 EGF-R)”, J. Immunol. 173(10):6472-6480 (Nov. 2004).
Ruiz PJ, et al. “Idiotypic immunization induces immunity to mutated p53 and tumor rejection”, Nat. Med., 4(6):710-712 (Jun. 1998).
Fenton RG, et al, “Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressingEscherichia coli”, J. Natl. Cancer. Inst., 87(24):1853-1861 (Dec. 1995).
Khleif SN, et al., “A phase 1 vaccine trial with peptides reflectingrasoncogene mutations of solid tumors”, J. Immunother., 22(2):155-165 (Mar. 1999).
Moscatello DK, et al., “A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors”, Cancer Res., 57:1419-1424 (Apr. 1997).
Pinilla-Ibarz J, et al., “CML vaccines as a paradigm of the specific immunotherapy of cancer”, Blood Rev., 14:111-120 (Jun. 2000).
Van Denderen J, et al., “Antibody recognition of the tumor-specificber-abljoining region in chronic myeloid leukemia”, J. Exp. Med., 169:87-98 (Jan. 1989).
Somasundaram R, et al, “Human Leukocyte Antigen-A2—Restricted CTL responses to Mutated BRAF Peptides in Melanoma Patients”, Cancer Res., 66(6):3287-3293 (Mar. 2006).
Andersen MH et al., “Immunogenicity of constitutively activeV599EBRaf”, Cancer Res., 64:5456-5460 (Aug. 2004).
Marincola FM, et al., “Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situlesions”, J. Immunother., 19(3):192-205 (May 1996).
Scanlan MJ, et al., “Characterization of human colon cancer antigens recognized by autologous antibodies”, Int. J. Cancer, 76:652-658 (Jan. 1998).
Baurain JF, et al., “High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene”, J. Immunol., 164(11):6057-6066 (Jun. 2000).
Gambacorti-Passerini C, et al., “Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARa present in acute promyelocytic leukemia cells” Blood, 81(5):1369-1375 (Mar. 1993).
Wang RF and Rosenberg SA., “Human tumor antigens for cancer vaccine development”, Immunol. Rev., 170:85-100 (Aug. 1999).
Brose MS et al., “BRAFandRASmutations in human lung cancer and melanoma” Cancer Res., 62:6997-7000 (Dec. 2002).
Pollock PM, et al., “High frequency of BRAF mutations in nevi”, Nat. Genet., 33:19-20 (Jan. 2003, e-publication Nov. 2002).
Michaloglou C., et al., “BRAFE600-associated senescence-like cell cycle arrest of human naevi”, Nature, 436(4):720-724 (Aug. 2005).
Sharkey MS et al, “CD4+T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation”, Cancer Res., 64:1595-1599 (Mar. 2004).
Takahashi M, et al., “Antibody to ras proteins in patients with colon cancer”, Clin. Cancer Res., 1:1071-1077 (Oct. 2005).
Davies, H, et al., “Mutations of the BRAF gene in human cancer”, Nature, 417:949-954 (Jun. 2002).
Terasaki, PI and Gjertson, DW, “HLA 1997: UCLA Tissue Typing Laboratory”, p. 174-427 (1997), Los Angeles, California.
Herlyn Dorothee
Otvos, Jr. Laszlo
Somasundaram Rajasekaran
Howson & Howson LLP
Huff Sheela J
The Wistar Institute of Anatomy and Biology
LandOfFree
Methods and compositions for treating melanoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating melanoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating melanoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4191781